跳到正文
PR Newswire Health·· 1 小时前AI 评分10

Novavax 将于 2026 年 11 月 5 日公布 2026 年第三季度财务业绩

Novavax to Report Third Quarter 2026 Financial Results on November 5, 2026

AI 导读

Novavax 计划于 2026 年 11 月 5 日美股开盘前公布 2026 年第三季度财务业绩,并于美东时间当日 8:30 举行网络直播和电话会议讨论业绩及运营亮点。网络直播回放将在活动结束约两小时后提供。

正文 · 原文

, /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX) today announced that the Company plans to release its third quarter 2026 financial results before the open of the U.S. financial markets on Thursday, November 5, 2026. Following the release, Company management will host a webcast and conference call at 8:30 a.m. Eastern Time (ET) to discuss financial results and operational highlights.

Conference call details:

Date:

November 5, 2026

Time: 

8:30 a.m. ET

URL to register phone:

Register Here

Dial-in number:

(+1) 888-880-3330 (U.S.) or (+1) 646-357-8766 (International)

Webcast:

The live webcast can be accessed at ir.novavax.com/events

  • Participants can join the conference call without operator assistance by registering and entering their phone number with the above URL to receive an instant automated call back.
  • Participants can also dial direct to be entered into the call by an operator and will be prompted to request to join the Novavax, Inc. call.
  • To ensure a timely connection, it is recommended that participants join at least 10 minutes prior to the scheduled start time.

A replay of the webcast will be available at  ir.novavax.com/events and over the phone approximately two hours after the event:

Replay dial-in number:

(+1) 800-770-2030 (U.S.) or (+1) 609-800-9909 (International)

Passcode:

 5780712# 

About Novavax
Novavax, Inc. (Nasdaq: NVAX) tackles some of the world's most pressing health challenges with its scientific expertise in vaccines and its proven technology platform, including its Matrix-M® adjuvant and protein-based nanoparticles. The Company's corporate growth strategy is designed to deliver value via three key strategic pillars: partnering its technology, capital-efficient research and development (R&D) innovation and a lean and efficient operating model. This includes maximizing impact through partnerships for its marketed products (Nuvaxovid™, R21/Matrix-M™), Matrix technology and R&D assets. Please visit novavax.com and LinkedIn for more information. 

Contacts:

Investors
Naina Zaman 
240-410-5353 
[email protected] 

Media 
Yvonne Sprow 
240-720-7804 
[email protected] 

SOURCE Novavax, Inc.

来源:PR Newswire Health · prnewswire.com

AI 摘要声明:站内标题、摘要与推荐理由由模型基于公开来源生成,属机器生成内容,非原文;本页内容仅供医药行业信息参考,不构成医疗建议、诊断或用药依据。